Jennifer French
Psychiatry · Glendale, CONPI 1801244207
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $84,335 of the $115,462 with a category attached, or 73.0%. AbbVie accounts for 84.3% of it on its own, with 24 other manufacturers making up the rest. Among psychiatry clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 748 payments — averaging $154.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$97K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$11K
- Lundbeck LLC$1K
- Tris Pharma Inc$821
- Vanda Pharmaceuticals Inc.$759
- Takeda Pharmaceuticals U.S.A., Inc.$605
- plus $4K from 19 others
What the payments were for
- Consulting fees$5,4005%
- Speaking & faculty fees$84,33573%
- Travel & lodging$11,15110%
- Food & beverage$14,52913%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 338 | $97,339 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 75 | $10,963 |
| Lundbeck LLC | 67 | $1,332 |
| Tris Pharma Inc | 20 | $821 |
| Vanda Pharmaceuticals Inc. | 38 | $759 |
| Takeda Pharmaceuticals U.S.A., Inc. | 30 | $605 |
| Otsuka America Pharmaceutical, Inc. | 28 | $532 |
| Teva Pharmaceuticals USA, Inc. | 18 | $530 |
| Alkermes, Inc. | 25 | $499 |
| Ironshore Pharmaceuticals Inc. | 22 | $387 |
| Neurocrine Biosciences, Inc. | 19 | $378 |
| Corium, LLC | 10 | $230 |
| Sunovion Pharmaceuticals Inc. | 17 | $227 |
| Johnson & Johnson | 9 | $167 |
| Sage Therapeutics, LLC | 6 | $102 |
| E.r. Squibb & Sons, L.L.C. | 5 | $98 |
| Supernus Pharmaceuticals, Inc. | 5 | $93 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $71 |
| Adlon Therapeutics L.p. | 3 | $67 |
| Axsome Therapeutics, Inc. | 2 | $66 |
| Almatica Pharma LLC | 2 | $60 |
| Avion Pharmaceuticals | 2 | $48 |
| Idorsia Pharmaceuticals US Inc | 2 | $36 |
| Bausch Health US, LLC | 2 | $32 |
| Eisai Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$92,531
- CAPLYTA$9,587
- UZEDY$123
- Dyanavel XR$116
How this compares
$115,462 in reported general payments places this provider in the 95th percentile of 559 psychiatry providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bupropion XlBupropion Hcl | 17 | $1,347 |
| Buspirone Hcl | 13 | $133 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Glendale
- John HardyPueblo$828K
- Larry SandersLittleton$760K
- Jeffrey RichmondDenver$424K
- Charles ParkLone Tree$89K
- Cynthia EppersonAurora$64K
- Brian WiseCentennial$44K
- Robert CowanCentennial$29K
- Brenda CzabanDenver$25K
- John DequardoPueblo$17K
- Robert ClarkDenver$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.